# OnCo record indolent-systemic-mastocytosis (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/indolent-systemic-mastocytosis/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "indolent-systemic-mastocytosis" ;
  schema:name "Indolent and smouldering systemic mastocytosis"@en ;
  schema:alternateName "ISM"@en, "Indolent SM"@en, "Smouldering systemic mastocytosis"@en, "Bone marrow mastocytosis"@en, "Non-advanced systemic mastocytosis"@en ;
  schema:description "Indolent systemic mastocytosis is the common, slow form of this rare blood disorder, in which KIT-mutant mast cells build up in the marrow and skin and release histamine that causes flushing, itching, stomach pain, bone thinning and sometimes severe allergic reactions. Life expectancy is near normal, antihistamines and adrenaline control symptoms, and low-dose avapritinib was approved in 2023."@en ;
  schema:url <https://onco.cc/cancers/indolent-systemic-mastocytosis/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mastocytosis> ;
  schema:citation <https://doi.org/10.1056/EVIDoa2200339>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478>, <https://en.wikipedia.org/wiki/Mastocytosis> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/advanced-systemic-mastocytosis/>, <https://onco.cc/cancers/systemic-mastocytosis/>, <https://onco.cc/cancers/essential-thrombocythaemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/kit/> ;
  onco:drugs <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/drugs/elenestinib/>, <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/interferon-alfa/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/molecular-response/> ;
  onco:trials <https://onco.cc/trials/nct03731260/>, <https://onco.cc/trials/nct04910685/>, <https://onco.cc/trials/nct05186753/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/>, <https://onco.cc/key-papers/paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023/> ;
  onco:pipeline <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/drugs/elenestinib/>, <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/trials/nct04910685/>, <https://onco.cc/trials/nct05186753/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/targets/kit/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/technologies/epro-symptom-monitoring/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/trials/nct03731260/>, <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/drugs/elenestinib/>, <https://onco.cc/trials/nct04910685/>, <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/trials/nct05186753/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/molecular-response/> .